In order to promote China-Canada medical technology cooperation and promote the effective transformation of excellent medical achievements in Canada, “Canada medical project exchange meeting（Beijing station）” was successfully held in Beijing Beiguang Building workshop 761 on September 14, 2018.The activity was hosted by Worldiscoveries Asia from the university of western Ontario, Beijing ICI, Northern technology exchange market, undertaken by 761 workshop (Beijing) science and technology development co., LTD, co-organized by TGN, Beijing maker space and Beijing Ontario S&T innovation cooperation center.
As the annual special activity of Worldiscoveries Asia, WD Asia invited 6 representatives from Canadian innovative enterprises, universities and research institutes to conduct the project roadshow, involving tumor therapy, biological agents, medical imaging, medical supplies and other medical fields. The activity attracted more than 50 representatives from the investment community, medical industry, research institutions and other domestic units.
At the meeting, representatives of the Canadian medical delegation introduced their institutions and projects. Ms Lisa Cechetto, the chief executive of the technology transfer center of the university of western Ontario introduced the technology transfer center. The university of western Ontario is the first Canadian university to have permanent technology transfer offices in Hong Kong and Nanjing. The technology transfer center of the university of western Ontario is the gateway of scientific and technological cooperation between Ontario, Canada, China and even Asia. Her projects include “time-resolved dynamic angiography CT imaging technology”, “orthopaedic tools to extract long-handled prostheses” and “surgical navigation tools”.
Michael Waterston, CEO and founder of Radialis, described in detail the company’s “PET imaging device for breast cancer detection,” which has developed a new low-dose, PET imaging sensor that covers the entire breast. Full-width detectors allow simultaneous imaging of the entire breast, speeding up image acquisition (high outpatient volume).Low-dose PET imaging is comparable to that of mammography and can be used for more extensive screening of breast cancer. Its high sensitivity has obvious advantages over high-density breast population.
Front Line medical company’s chief executive and founder of Asha Parekh, introduces its products “new blocking balloon for trunk trauma hemorrhage control”, the company patented product COBRA ™ blocking balloon (control hemorrhage, recovery aorta balloon block) can provide a solution to prevent internal bleeding in emergency situations where pressure cannot be applied to stop bleeding. At the meeting, the animal clinical trial of the product video more vividly and fully demonstrated the advantages of the product, safety, efficiency, portability, and easy to use.
Dr. Ali Riazi, CEO of Trillium Meditec, introduced two types of products. Inflawell is a patented botanical extract containing antioxidants and natural lipids. In-vitro experiments showed that the active ingredients in the plant extract had strong anti-inflammatory effect and the effect of promoting neurite growth. In addition, the FLEXZEN, a polyacrylamide (PAAG) hydrogel for osteoarthritis, offers superior lubrication and viscosity supplementation, and its slow biodegradation reduces the risk of long-term complications in patients.
Dr Jean-simon Diallo, a scientist at the Ottawa hospital research institute, detailed his project, “Scalable Vector Manufacturing Enhancement Using Viral Sensitizers”. The team found that small molecular compounds that can greatly increase virus production can increase virus production by up to 1,000 times. They have been working with vaccine companies for more than four years to increase production of viral vaccines to meet the growing global market.
Dr. James Koropatnick, a renowned cancer scientist from London health science center, Canada, introduced his project “cancer therapy for RAD51 and BRCA2”. Their research showed that IBR2 and IBR120 are candidate anticancer drugs used in combination with therapeutic anticancer cytotoxic drugs, which have the potential to enhance a series of targeted drugs. His team will present the data of IBR120 synergist over IBR2 at the 19th world lung cancer congress of the international lung cancer association (IASLC WCLC 2018). At the meeting Dr. James Koropatnick also extended a sincere invitation to the audience.
This Canadian medical project exchange activity will play a positive role in promoting the transfer and transformation of excellent Canadian medical scientific and technological achievements to Beijing and even China and promoting the scientific and technological exchanges and cooperation between China and Canada. In the future, the technology transfer center of the university of western Ontario will continue to introduce excellent scientific and technological achievements of Canada to China and make due contributions to scientific and technological cooperation and exchanges between the two countries.